Related Experiment Video
Updated: Jun 27, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Melanoma: targeting signaling pathways and RaLP
Luigi Pasini1, Margherita Y Turco, Lucilla Luzi
1IFOM-IEO Campus, European Institute of Oncology, Department of Experimental Oncology, Via Adamello, 16 20139 Milan, Italy.
Expert Opinion on Therapeutic Targets
|December 10, 2008
Summary
Metastatic melanoma is aggressive, with limited treatment success. Rai-like protein (RaLP), a novel target, shows promise for melanoma-specific therapies, potentially improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Metastatic melanoma is a highly aggressive cancer with poor prognosis.
- Current therapies offer limited survival benefits for advanced-stage disease.
- Rai-like protein (RaLP) is selectively expressed during melanoma metastasis.
Purpose of the Study:
- To review current therapeutic strategies for metastatic melanoma.
- To evaluate Rai-like protein (RaLP) as a potential therapeutic target.
Main Methods:
- Discussion of key signaling pathways in melanoma metastasis.
- Review of existing pharmacological inhibitors for these pathways.
Main Results:
- Rai-like protein (RaLP) is identified as a novel therapeutic target.
- RaLP's selective expression suggests melanoma-specific targeting potential.
Conclusions:
- Rai-like protein (RaLP) represents a promising new drugable target for metastatic melanoma.
- Targeting RaLP could lead to improved treatment outcomes for advanced melanoma.
More Related Videos
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...